Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.65 |
| ▸ | MAPT | P10636 | 6/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | FBP1 | P09467 | 2/20 | 0.57 |
| ▸ | VCP | P55072 | 1/20 | 0.57 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | MAOB | P27338 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.52 |
| ▸ | G6PD | P11413 | 2/20 | 0.51 |
| ▸ | RECQL | P46063 | 2/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.51 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11795297 | 0.89 | NFE2L2 (0.64) | NFE2L2ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL16634847 | 0.87 | ALDH1A1 (0.76) | NFE2L2ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL16634831 | 0.87 | ALDH1A1 (0.76) | NFE2L2ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL10710863 | 0.86 | NFE2L2 (0.56) | NFE2L2ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL5250012 | 0.85 | NFE2L2 (0.73) | NFE2L2ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL11408255 | 0.83 | G6PD (0.67) | NFE2L2ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL14880346 | 0.83 | NFE2L2 (0.69) | NFE2L2ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL1405314 | 0.81 | NFE2L2 (1.00) | NFE2L2ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL12018202 | 0.81 | ALDH1A1 (0.65) | NFE2L2ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL1405312 | 0.81 | NFE2L2 (1.00) | NFE2L2ALDH1A1MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110172234-A1 | METHODS AND COMPOSITIONS OF TRAIL-DEATH RECEPTOR AGONISTS/ACTIVATORS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2011-07-14 | — | — | US | disclosed |
| US-7915245-B2 | Using small molecules as binding ligands, for the recruitment of Fas-associated death domain protein, activation of death-inducing signaling complex, caspase-8, and apoptosis in malignant cells; anticarcinogens, antitumor agents; enhanced cellular differentiation, minimizing cytolysis to healthy cells | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2011-03-29 | — | — | US | disclosed |
| US-20080214547-A1 | METHODS AND COMPOSITIONS OF TRAIL-DEATH RECEPTOR AGONISTS/ACTIVATORS | UNIVERSITY OF MARYLAND, BALTIMORE | 2008-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214547-A1 | METHODS AND COMPOSITIONS OF TRAIL-DEATH RECEPTOR AGONISTS/ACTIVATORS | BID, BAD, MCL1 | NFE2L2 2158/4885ALDH1A1 3768/4885MAPT 3638/4885 |
| US-20110172234-A1 | METHODS AND COMPOSITIONS OF TRAIL-DEATH RECEPTOR AGONISTS/ACTIVATORS | BID, BAD, MCL1 | NFE2L2 2158/4885ALDH1A1 3768/4885MAPT 3638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.